{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T05:11:30Z","timestamp":1775193090825,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Euro J of Neurology"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>HER\u2010MES was the first head\u2010to\u2010head study of erenumab against topiramate (standard of care). This post hoc analysis of the HER\u2010MES study evaluated the effect of erenumab versus topiramate on patient\u2010reported outcomes at week 24.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adult patients with episodic or chronic migraine (<jats:italic>n<\/jats:italic>\u2009=\u2009777) were randomized (1:1) to monthly subcutaneous erenumab (<jats:italic>n<\/jats:italic>\u2009=\u2009389) or daily oral topiramate (<jats:italic>n<\/jats:italic>\u2009=\u2009388). Migraine\u2010related disability, as measured by the Headache Impact Test 6 (HIT\u20106) and Short Form 36 Health Survey version 2 (SF\u201036v2), was analysed in the entire study cohort and true completers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the erenumab group (vs. topiramate), significant improvements were reported in Headache Impact Test 6 total scores (composite populations, \u221210.88 vs. \u22127.72; true completers, \u221211.92 vs. \u221210.61) and a higher proportion of patients achieved a \u22655\u2010point reduction from baseline with erenumab (composite populations, 72.2% vs. 53.9%; true completers, 79.64% vs. 71.43%). The adjusted mean change from baseline in the SF\u201036v2 score was greater with erenumab for both physical component summary (composite population, 5.48 vs. 3.63; true completers, 5.95 vs. 5.23) and mental component summary (composite populations, 1.00 vs. \u22121.18; true completers, 1.74 vs. \u22120.33). A higher proportion of patients on erenumab versus topiramate had a \u22655\u2010point improvement in SF\u201036v2 for the physical component summary (composite populations, 47.7% vs. 37.4%; true completers, 52.1% vs. 48.9%) and mental component summary (composite populations, 25.3% vs. 16.8%; true completers, 27.3% vs. 17.7%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This post hoc analysis demonstrated that patients treated with erenumab had significant improvements in headache impact and quality of life as measured by patient\u2010reported outcomes versus patients treated with topiramate.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ene.16437","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T08:14:30Z","timestamp":1723450470000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Erenumab versus topiramate: migraine\u2010related disability, impact and health\u2010related quality of life"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8527-0725","authenticated-orcid":false,"given":"Uwe","family":"Reuter","sequence":"first","affiliation":[{"name":"Department of Neurology Charite Universitatsmedizin Berlin  Berlin Germany"},{"name":"Universitatsmedizin Greifswald  Greifswald Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Heinze","sequence":"additional","affiliation":[{"name":"Schmerzklinik Kiel Migraine and Headache Center  Kiel Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Gendolla","sequence":"additional","affiliation":[{"name":"Praxis Gendolla  Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Sieder","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH  Nuremberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Hentschke","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH  Nuremberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414547138"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416678382"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12055"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0923-6"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418789072"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-324396"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.8.965"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.4.490"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2007.01326.x"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14692"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01431-x"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01682-2"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211053571"},{"key":"e_1_2_15_18_1","unstructured":"European Medicines Agency.PRAC recommends new measures to avoid topiramate exposure in pregnancy. Accessed June 25 2024.https:\/\/www.ema.europa.eu\/en\/news\/prac\u2010recommends\u2010new\u2010measures\u2010avoid\u2010topiramate\u2010exposure\u2010pregnancy"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01511-y"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182535d0c"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417731348"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S156279"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14013"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1023\/a:1026119331193"},{"key":"e_1_2_15_25_1","first-page":"23","volume-title":"SF36 Health Survey: Manual and Interpretation Guide","author":"Ware J","year":"1993"},{"key":"e_1_2_15_26_1","volume-title":"SF\u201036 Physical and Mental Health Summary Scales. A User's Manual","author":"Ware J","year":"1994"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2005.00612.x"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X104731"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14053"}],"container-title":["European Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ene.16437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T04:45:25Z","timestamp":1757565925000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ene.16437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1111\/ene.16437"],"URL":"https:\/\/doi.org\/10.1111\/ene.16437","archive":["Portico"],"relation":{},"ISSN":["1351-5101","1468-1331"],"issn-type":[{"value":"1351-5101","type":"print"},{"value":"1468-1331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,12]]},"assertion":[{"value":"2024-05-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e16437"}}